High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: study protocol for TBTC Study 31/ACTG A5349 phase 3 clinical trial

INTRODUCTION: Phase 2 clinical trials of tuberculosis treatment have shown that once-daily regimens in which rifampin is replaced by high dose rifapentine have potent antimicrobial activity that may be sufficient to shorten overall treatment duration. Herein we describe the design of an ongoing phas...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Contemp Clin Trials
मुख्य लेखकों: Dorman, Susan E., Nahid, Payam, Kurbatova, Ekaterina V., Goldberg, Stefan V., Bozeman, Lorna, Burman, William J., Chang, Kwok-Chiu, Chen, Michael, Cotton, Mark, Dooley, Kelly E., Engle, Melissa, Feng, Pei-Jean, Fletcher, Courtney V., Ha, Phan, Heilig, Charles M., Johnson, John L., Lessem, Erica, Metchock, Beverly, Miro, Jose M., Nhung, Nguyen Viet, Pettit, April C., Phillips, Patrick P.J., Podany, Anthony T., Purfield, Anne E., Robergeau, Kathleen, Samaneka, Wadzanai, Scott, Nigel A., Sizemore, Erin, Vernon, Andrew, Weiner, Marc, Swindells, Susan, Chaisson, Richard E.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7307310/
https://ncbi.nlm.nih.gov/pubmed/31981713
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cct.2020.105938
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन